Shineco Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jennifer Zhan

Algemeen directeur

US$73.4k

Totale compensatie

Percentage CEO-salaris	78.3%
Dienstverband CEO	3.3yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.7yrs
Gemiddelde ambtstermijn bestuur	3.2yrs

Recente managementupdates

Recent updates

Shineco CEO steps down, new CEO appointed

May 07

Shineco rallies on proposal to acquire 51% equity interests in Mayah Biological

May 04

Analyse CEO-vergoeding

Hoe is Jennifer Zhan's beloning veranderd ten opzichte van Shineco's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	US$73k	US$58k	-US$31m
Mar 31 2024	n/a	n/a	-US$14m
Dec 31 2023	n/a	n/a	-US$14m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	US$70k	US$60k	-US$10m
Mar 31 2023	n/a	n/a	US$2m
Dec 31 2022	n/a	n/a	US$2m
Sep 30 2022	n/a	n/a	US$2m
Jun 30 2022	US$70k	US$60k	-US$8m

Compensatie versus markt: De totale vergoeding ($USD 73.41K ) Jennifer } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 653.78K ).

Compensatie versus inkomsten: De vergoeding van Jennifer is gestegen terwijl het bedrijf verliesgevend is.

CEO

Jennifer Zhan (36 yo)

3.3yrs

Tenure

US$73,408

Compensatie

Ms. Jennifer Zhan has been Chief Executive Officer of Shineco, Inc. since July 15, 2021 and has been its Executive Director since July 14, 2021. She was a founding partner of Tian ‘Ang capital Beijing Inve...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jennifer Zhan	CEO & Executive Director	3.3yrs	US$73.41k	geen gegevens
Sai Wang	CFO & Director	9.8yrs	US$98.00k	0.62% $ 28.6k
Xiqiao Liu	COO & Executive Director	2.7yrs	US$10.00k	0% $ 0
Wang Xiaohui	Executive President	less than a year	geen gegevens	geen gegevens
Fenming Liu	Chief Scientist	no data	geen gegevens	geen gegevens
Qiyin Sun	Chief Medical Consultant	2.8yrs	geen gegevens	geen gegevens
Chi Keung Yan	Chief Strategy Officer	less than a year	geen gegevens	geen gegevens

2.7yrs

Gemiddelde duur

45yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SISI wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jennifer Zhan	CEO & Executive Director	3.3yrs	US$73.41k	geen gegevens
Sai Wang	CFO & Director	8.4yrs	US$98.00k	0.62% $ 28.6k
Xiqiao Liu	COO & Executive Director	2.7yrs	US$10.00k	0% $ 0
Aamir Quraishi	Independent Director	2.3yrs	US$10.00k	geen gegevens
Hu Li	Independent Director	3.2yrs	US$10.00k	geen gegevens
Mike Zhao	Independent Chairman of the Board	3.3yrs	US$10.00k	geen gegevens
Mingyong Hu	Independent Director	less than a year	geen gegevens	geen gegevens

3.2yrs

Gemiddelde duur

46yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SISI wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Shineco Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Shineco, Inc., Annual General Meeting, Oct 21, 2024

Shineco, Inc., Annual General Meeting, Feb 01, 2024

Shineco, Inc. Announces the Appointment of Two New Executive Officers

Shineco, Inc., Annual General Meeting, Jun 28, 2023

High number of new and inexperienced directors

Shineco, Inc. Appoints Aamir Ali Quraishi as Independent Director

Recent updates

Full year 2024 earnings released: US$5.89 loss per share (vs US$5.43 loss in FY 2023)

Shineco, Inc., Annual General Meeting, Oct 21, 2024

Shineco Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Requirement

Shanchun Huang Engages in Discussions with Shineco

Shanchun Huang Engages in Discussions with Shineco

Shineco, Inc. has filed a Follow-on Equity Offering.

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

Shineco Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Requirement Under Nasdaq Listing Rule 5550(a)(2)

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

New major risk - Financial position

Shineco, Inc., Annual General Meeting, Feb 01, 2024

Shineco, Inc. Announces the Appointment of Two New Executive Officers

New major risk - Share price stability

New major risk - Financial position

Full year 2023 earnings released: US$0.54 loss per share (vs US$2.60 loss in FY 2022)

Shineco Not Regains Compliance with the Nasdaq's Minimum Bid Price Requirement

Shineco, Inc.'S Subsidiary, Changzhou Biowin Pharmaceutical Co., Ltd., Receives Marketing Approval from China's Regulatory Body for Its Cardiac 5 Minute Test

New major risk - Market cap size

Shineco, Inc., Annual General Meeting, Jun 28, 2023

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.30 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.32 loss in 2Q 2022)

Shineco, Inc. (NasdaqCM:SISI) signed a letter of intent to acquire 80% stake in Dream Partner Limited for $40 million.

First quarter 2023 earnings released: US$0.17 loss per share (vs US$1.34 loss in 1Q 2022)

High number of new and inexperienced directors

Shineco Receives Deficiency Letter from Nasdaq

Full year 2022 earnings released: US$2.60 loss per share (vs US$4.73 loss in FY 2021)

Shineco, Inc. Appoints Aamir Ali Quraishi as Independent Director

Shineco, Inc. Resigns Yanzeng as Member of the Board of Directors

High number of new and inexperienced directors

Shineco, Inc. Announces Management Changes

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Shineco, Inc. Appoints Qiyin Sun as Chief Medical Consultant

High number of new directors

Shineco, Inc. (NasdaqCM:SISI) entered into an agreement to acquire 51% stake in Xiang Peng You Kang (Beijing) Technology Co., Ltd.

Independent Director Harry Edelson has left the company

High number of new directors

Third quarter 2021 earnings released: US$2.36 loss per share (vs US$1.26 loss in 3Q 2020)

Shineco CEO steps down, new CEO appointed

Shineco, Inc. (NasdaqCM:TYHT) signed a non-binding terms of proposal to acquire a 51% stake in Mayah Biological Holdings Limited.

Shineco rallies on proposal to acquire 51% equity interests in Mayah Biological

Shineco, Inc. announced delayed 10-Q filing

New 90-day high: US$4.15

New 90-day high: US$3.82

New 90-day high: US$3.31

First quarter 2021 earnings released: US$0.35 loss per share

Full year earnings released - US$2.25 loss per share

New 90-day low - US$2.71

Shineco, Inc. Announces Management Changes

Shineco, Inc. (NasdaqCM:TYHT) signed a non-binding Letter of Intent to acquire 73.7% stake in Changzhou Biowin Pharmaceutical Co., Ltd from Beijing Kanghuayuan Technology Development Co., Ltd and Changzhou Kelinbo Venture Capital Partnership (limited partnership) for $25 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd